Published • loading... • Updated
GSK Strikes up to $750m Deal for Cancer-Targeting Drug
The agreement gives GSK full global rights as it expands its cancer pipeline ahead of looming patent losses on HIV medicines.
- On Tuesday, GSK agreed to acquire a trispecific TCE from China-based biotechnology firm Chimagen Biosciences in a deal worth up to $750 million for full global rights.
- CEO Luke Miels is leading an oncology expansion to bolster GSK's cancer franchise, responding to looming patent losses on the company's top-selling HIV medicines.
- The trispecific TCE acts as an engineered protein that brings T-cells and tumor cells together while blocking immune checkpoints, enhancing cancer-killing ability with reduced off-target effects.
- GSK plans to develop and commercialize the drug for multiple myeloma, a type of blood cancer, with initial phase 1 trials expected to begin in 2027.
- This purchase follows an active period for the company: the $10.6 billion acquisition of Nuvalent earlier this year, a 2024 deal with Chimagen worth up to $850 million, and Blenrep's October 2025 market return.
Insights by Ground AI
15 Articles
15 Articles
GSK strikes up to $750 million deal for cancer-targeting drug
·London, United Kingdom
Read Full Article
British global pharmaceutical manufacturer GSK has signed a notable licensing agreement with Chengdu-based biotechnology firm Chimagen Biosciences. Under the agreement, GSK will be able to treat multiple myeloma, a type of blood cancer...
Roundup: GSK Acquires Trispecific T Cell-Engager from Chimagen, Sanofi & Cheplapharm Form Strategic Partnership
GSK agrees to acquire a trispecific T cell engager for multiple myeloma from Chimagen Biosciences, while Sanofi is offloading 20 mature medicines and three manufacturing sites to Cheplapharm.
Coverage Details
Total News Sources15
Leaning Left0Leaning Right1Center3Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
C 75%
R 25%
Factuality
To view factuality data please Upgrade to Premium
